Inventor · disambiguated record
Jiabing Wang
Also filed as: WANG JIABING
30 granted patents·44 pending applications·323 citations·filing 1996–2024
96Inventor score
Files withBETTA PHARMACEUTICALS CO LTD41MERCK & CO INC12ASTRAZENECA AB4DIZAL JIANGSU PHARMACEUTICAL CO LTD2FURUYAMA HIDETOMO2
Top patents by PatentIndex Score
74 records- 0196US6048861AIntegrin receptor antagonistsMERCK & CO INC·Filed 1998·Granted Apr 11, 2000·100 cites·47 claims
- 0293US10822334B2ErbB receptor inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Nov 3, 2020·4 cites·6 claims
- 0389US11365196B2FGFR inhibitor and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2018·Granted Jun 21, 2022·6 cites·33 claims
- 0489US6017926AIntegrin receptor antagonistsMERCK & CO INC·Filed 1998·Granted Jan 25, 2000·108 cites·48 claims
- 0588US7268153B2N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulatorsMERCK & CO INC·Filed 2005·Granted Sep 11, 2007·14 cites·13 claims
- 0688US6784190B2Integrin receptor antagonistsMERCK & CO INC·Filed 2001·Granted Aug 31, 2004·17 cites·23 claims
- 0784US7056909B2Alpha v integrin receptor antagonistsMERCK & CO INC·Filed 2001·Granted Jun 6, 2006·21 cites·14 claims
- 0883US8207169B2Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula DFURUYAMA HIDETOMO·Filed 2009·Granted Jun 26, 2012·9 cites·5 claims
- 0983US8008317B2Inhibitors of akt activtiyMERCK SHARP & DOHME·Filed 2006·Granted Aug 30, 2011·9 cites·4 claims
- 1083US6472403B2αV integrin receptor antagonistsMERCK & CO INC·Filed 2001·Granted Oct 29, 2002·20 cites·14 claims
- 1179US9066979B2Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptorASTRAZENECA AB·Filed 2014·Granted Jun 30, 2015·3 cites·16 claims
- 1276US11845762B2Compound functioning as bromodomain protein inhibitor, and compositionBETTA PHARMACEUTICALS CO LTD·Filed 2022·Granted Dec 19, 2023·0 cites·8 claims
- 1374US8691825B2Inhibitors of AKT activityCHEN QI·Filed 2010·Granted Apr 8, 2014·3 cites·4 claims
- 1473US2025223286A1Immunomodulators, compositions and methods thereofBETTA PHARMACEUTICALS CO LTD·Filed 2024·Application pending·0 cites
- 1572US11053238B2Benzimidazole derivatives, preparation methods and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2017·Granted Jul 6, 2021·1 cites·33 claims
- 1672US7629367B2N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulatorsMERCK & CO INC·Filed 2005·Granted Dec 8, 2009·1 cites·1 claims
- 1771US9375432B2Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptorASTRAZENECA AB·Filed 2015·Granted Jun 28, 2016·1 cites·18 claims
- 1861US11447492B2ERBB receptor inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Sep 20, 2022·0 cites·15 claims
- 1960US7763659B2N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulatorsMERCK SHARP & DOHME·Filed 2007·Granted Jul 27, 2010·0 cites·1 claims
- 2060US2024352053A1Salt and crystal form of egfr inhibitor, and composition and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2160US2025051301A1Mutant idh1 and idh2 inhibitor and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 2260US2025361241A1Hpk1 inhibitor and medical use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 2360US2025223300A1Macrocyclic compound and pharmaceutical composition and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 2459US9718806B2Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptorASTRAZENECA AB·Filed 2016·Granted Aug 1, 2017·0 cites·13 claims
- 2558US12043622B2Crystal form of compound for inhibiting the activity of CDK4/6 and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Granted Jul 23, 2024·0 cites·9 claims
- 2658US8536193B2Inhibitors of AKT activityFURUYAMA HIDETOMO·Filed 2009·Granted Sep 17, 2013·0 cites·2 claims
- 2758US2025042853A1Bicyclic compound and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2857US2025154149A1Pharmaceutical composition and method for preparing active ingredient compound thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 2956US12187713B2Immunomodulators, compositions and methods thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Granted Jan 7, 2025·0 cites·20 claims
- 3056US2018016259A1Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptorASTRAZENECA AB·Filed 2017·Application pending·0 cites
- 3155US2024336594A1Six-membered aryl or heteroaryl amides, and composition and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 3255US2024246994A1Polymorph Of Imidazolidinone Compound, Preparation Method Therefor And Use ThereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 3355US2024299380A1Application of compound in preparation of drug for treating myelofibrosis and related symptoms/signs thereof, and use of compoundBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 3455US2023321100A1Cd73 inhibitor and application thereof in medicineBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3554US2024022501A1Data Packet Sending Method and DeviceHUAWEI TECH CO LTD·Filed 2023·Application pending·0 cites
- 3653US11466034B2Compound functioning as bromodomain protein inhibitor, and compositionBETTA PHARMACEUTICALS CO LTD·Filed 2018·Granted Oct 11, 2022·0 cites·22 claims
- 3753US2021340142A1Salt form and crystal form of novel azatricyclic compound and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 3852US2023339882A1Shp2 inhibitor and composition and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3951US2023391779A1Bicyclic compounds, compositions and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 4051US2023192705A1Shp2 inhibitors, compositions and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 4150US7625919B24-azasteroid derivatives as androgen receptor modulatorsMERCK & CO INC·Filed 2006·Granted Dec 1, 2009·0 cites·36 claims
- 4250US5900427AN-heteroarenesulfonyl-protected amino acid reagents for peptide synthesisWISCONSIN ALUMNI RES FOUND·Filed 1996·Granted May 4, 1999·6 cites·8 claims
- 4350US2022227796A1Egfr inhibitors, compositions and methods there ofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 4450US2023203055A1Fused ring compound and application thereof in medicineBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 4550US2023133169A1Egfr inhibitor, composition, and method for preparation thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 4650US2024174681A1Salt and crystalline forms of fgfr4 inhibitor and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 4750US2023053342A1Imidazolidinone compound, preparation method therefor and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 4849US2023062486A1Kras g12c inhibitor and pharmaceutical use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 4949US2023131025A1Quinolyl phosphine oxide compound, and composition and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 5049US2022402948A1Egfr inhibitor, composition and preparation method thereforBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jiabing Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →